Moderna Announces New England Journal Of Medicine Publication Of Phase 3 Clinical Safety And Efficacy Data For MRNA-1345, The Company's Investigational Respiratory Syncytial Virus Vaccine
Portfolio Pulse from Benzinga Newsdesk
Moderna, Inc. (NASDAQ:MRNA) has published positive Phase 3 clinical trial results for its mRNA-1345 RSV vaccine in The New England Journal of Medicine. The study, ConquerRSV, shows the vaccine's safety and efficacy, marking a significant step in RSV vaccine development and mRNA technology. Moderna, the sole developer of an mRNA-based RSV vaccine, plans a 2024 launch for mRNA-1345, pending regulatory approval. The vaccine is expected to be best-in-class and the only ready-to-use RSV vaccine in single-dose prefilled syringes.
December 15, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's positive Phase 3 trial results for its mRNA-1345 RSV vaccine could lead to regulatory approval and a 2024 product launch, potentially enhancing the company's product portfolio and revenue streams.
The publication of positive Phase 3 clinical trial results is a strong indicator of the vaccine's potential success and could lead to increased investor confidence. The anticipation of a new product launch, especially with a best-in-class profile, is likely to have a positive impact on Moderna's stock price in the short term. The company's track record with its COVID-19 vaccine may also contribute to positive market sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100